Drugs / MM-II
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | EU (EMA) | — | osteoarthritis, knee | 2025-07-31 | “Phase 3 completed Filing with EMA MM-II pain in osteoarthritis Phase 2 completed To enter partnership for commercialization” sunpharma.com ↗ “Filing with EMA MM-II pain in osteoarthritis Phase 2 completed To enter partnership for commercialization” sunpharma.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04506463 | Dec 2020 → May 2022 | osteoarthritis, knee | Sun Pharmaceutical Industries, Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-04-24 | Sun Pharmaceutical Industries, Inc. | Results Sun Pharma and Moebius Medical Announce Dual Publications on MM-II’s Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage sunpharma.com ↗
Findings demonstrate that a single injection of MM -II provided clinically meaningful pain relief through 26 weeks, with a favorable safety and tolerability profile |
| 2024-09-06 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain sunpharma.com ↗ |
| 2024-06-14 | Sun Pharmaceutical Industries, Inc. | Results Oral Presentation at EULAR 2024 of Data from Global Phase 2b Clinical Trial Demonstrates Durability of Pain Relief After a Single Injection of MM-II in Patients with Painful Knee Osteoarthritis (OA) sunpharma.com ↗
A single intra-articular injection of 3mL of MM-II provided greater pain relief than placebo for up to 26 weeks |
| 2023-03-22 | Sun Pharmaceutical Industries, Inc. | Results Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study sunpharma.com ↗
While the study did not achieve statistical significance on the primary outcome measure, it did show meaningful and sustained improvement across several clinical measures. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-24 | Sun Pharmaceutical Industries, Inc. | Sun Pharma and Moebius Medical Announce Dual Publications on MM-II’s Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage sunpharma.com ↗ |
| 2024-09-06 | Sun Pharmaceutical Industries, Inc. | Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain sunpharma.com ↗ |
| 2024-06-14 | Sun Pharmaceutical Industries, Inc. | Oral Presentation at EULAR 2024 of Data from Global Phase 2b Clinical Trial Demonstrates Durability of Pain Relief After a Single Injection of MM-II in Patients with Painful Knee Osteoarthritis (OA) sunpharma.com ↗ |
| 2023-03-22 | Sun Pharmaceutical Industries, Inc. | Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study sunpharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MM-II | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04506463 ↗ |